BioRegenx Inc. Sets Sights on National Exchange Uplisting with Legal Expertise

In a strategic move poised to elevate its market presence, BioRegenx, Inc., a health technology company specializing in microvascular and metabolic health, has engaged the renowned law firm Sichenzia Ross Ference Carmel LLP (SRFC) to guide its planned uplisting to a national securities exchange. This development, announced on May 13, 2025, underscores BioRegenx’s commitment to enhancing shareholder value and expanding its reach within the institutional investment community.

Strategic Legal Partnership

BioRegenx’s decision to partner with SRFC, a firm celebrated for its expertise in securities law and regulatory compliance, marks a pivotal step in its journey toward uplisting. “We are pleased to partner with SRFC, a firm with deep experience in securities law and regulatory compliance,” stated William Resides, Chief Executive Officer of BioRegenx. “Their proven track record guiding companies through uplisting transactions is an essential component of our capital markets roadmap, and their expertise will be instrumental as we prepare to meet the rigorous legal and governance standards required by national exchanges.”

Enhancing Shareholder Value

The planned uplisting to a senior national securities exchange, such as the Nasdaq or NYSE American, is anticipated to significantly enhance the liquidity and visibility of BioRegenx’s common stock. This strategic move is expected to not only attract a broader base of institutional investors but also strengthen the company’s market position. By aligning with SRFC, BioRegenx aims to navigate the complex legal and regulatory landscape effectively, ensuring compliance with the stringent requirements of national exchanges.

Financial Overview

As of May 12, 2025, BioRegenx’s stock closed at $0.0291, reflecting a notable recovery from its 52-week low of $0.0074 on April 6, 2025. The company’s market capitalization stands at approximately $16.17 million, with its shares traded on the OTC Bulletin Board. This financial backdrop highlights the potential impact of the uplisting on BioRegenx’s market valuation and investor interest.

Forward-Looking Perspective

BioRegenx’s engagement with SRFC is a testament to its proactive approach in pursuing growth opportunities and enhancing its corporate governance framework. As the company prepares for the uplisting process, stakeholders can anticipate a series of strategic initiatives aimed at bolstering its market presence and operational capabilities. This forward-looking perspective positions BioRegenx as a dynamic player in the health technology sector, poised for sustained growth and innovation.

In conclusion, BioRegenx’s strategic partnership with SRFC and its planned uplisting to a national exchange represent significant milestones in its corporate journey. By leveraging legal expertise and focusing on regulatory compliance, BioRegenx is well-positioned to unlock new growth avenues and deliver value to its shareholders.